BioNTech Sheds 1,860 Jobs and Warns on German Healthcare Reform as Oncology Bet Intensifies

BioNTech slashes 1,860 jobs, closes four sites, and redirects €500M to cancer research while facing regulatory headwinds in Germany and a leadership transition.

BioNTech is navigating a storm on two fronts. At home, Berlin’s planned healthcare reforms are casting a shadow over investment plans, while internally the company is executing one of the most aggressive restructurings in its history. The Mainz-based biotech has warned that shifting regulatory and reimbursement conditions in Germany could influence where and how it allocates capital — a particularly sensitive issue as it pours billions into a long-cycle oncology pivot.

The restructuring is already in full swing. By the end of 2027, BioNTech will close four sites, including its flagship locations in Marburg and Tübingen, cutting roughly 1,860 positions — nearly a quarter of its total workforce. The move is expected to generate annual savings of around €500 million, money that management says will be redirected entirely into cancer research. The message from the C-suite is blunt: the old vaccine-focused footprint no longer fits the new strategy.

The financial strain is visible in the numbers. First-quarter revenue shrank to just €118 million, while the net loss ballooned to €532 million. That deepens the urgency behind the cost-cutting and the pipeline push. At the recent ASCO annual meeting, BioNTech highlighted two key candidates: Pumitamig and Gotistobart, both part of a broader drive to target multiple tumour types and reduce dependence on Covid-related products.

Wall Street is split on the outlook. UBS analyst David Dai rates the stock a buy with a $135 price target, arguing that the oncology pipeline’s potential is being underestimated. Bernstein’s Jeffrey Walch is more cautious, setting a target of just $96 and seeing limited upside from current levels. The stock traded at €77.45 on Thursday, up 1.64% on the day but still down roughly 20% over the past twelve months and nearly 10% below its 200-day moving average.

That said, BioNTech enters this transformation with one formidable advantage: a fortress balance sheet. As of end of the first quarter, it held €16.8 billion in cash, cash equivalents and securities. That war chest gives it ample runway to fund clinical programmes without raising fresh capital. And the board has authorised a $1 billion share buyback programme over the next twelve months — a signal of capital discipline that doesn’t compromise pipeline investment.

The political headwinds, though, are unlikely to fade quickly. BioNTech has joined U.S. rival Eli Lilly in publicly criticising the federal government’s proposed health-system changes, warning that uncertainty over pricing and reimbursement could deter future investments in Germany. The company has declined to specify which projects might be affected, but the warning alone underscores how delicate the home-market environment has become.

Meanwhile, the leadership baton is about to pass. Founders U?ur ?ahin and Özlem Türeci will step down at year-end, handing a sprawling turnaround to a new management team. Their legacy includes an ambitious goal: securing market approval for ten cancer drugs by 2030. Key late-stage data are expected in the second half of this year, and an approval application for the antibody candidate BNT323 is planned before 2025 is out.

For now, the stock is caught in the gap between a promising pipeline and a punishing transition. The clinical readouts will ultimately decide whether the restructuring and reform noise fade into the background — or become the defining story of BioNTech’s next chapter.